Efficacy and Safety of Bimagrumab/BYM338 at 52 Weeks on Physical Function, Muscle Strength, Mobility in sIBM Patients

NCT01925209 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

251

Enrollment

INDUSTRY

Sponsor class

Conditions

Sporadic Inclusion Body Myositis

Interventions

DRUG: BYM338/bimagrumab
DRUG: Placebo

Sponsor

Novartis Pharmaceuticals